JP2005528359A5 - - Google Patents

Download PDF

Info

Publication number
JP2005528359A5
JP2005528359A5 JP2003577780A JP2003577780A JP2005528359A5 JP 2005528359 A5 JP2005528359 A5 JP 2005528359A5 JP 2003577780 A JP2003577780 A JP 2003577780A JP 2003577780 A JP2003577780 A JP 2003577780A JP 2005528359 A5 JP2005528359 A5 JP 2005528359A5
Authority
JP
Japan
Prior art keywords
transdermal
depression
dosage
buprenorphine
transdermal dosage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003577780A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005528359A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2003/008796 external-priority patent/WO2003079945A1/en
Publication of JP2005528359A publication Critical patent/JP2005528359A/ja
Publication of JP2005528359A5 publication Critical patent/JP2005528359A5/ja
Pending legal-status Critical Current

Links

JP2003577780A 2002-03-20 2003-03-20 うつ病の治療のためのブプレノルフィンの投与方法 Pending JP2005528359A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36635802P 2002-03-20 2002-03-20
PCT/US2003/008796 WO2003079945A1 (en) 2002-03-20 2003-03-20 Method of administering buprenorphine to treat depression

Publications (2)

Publication Number Publication Date
JP2005528359A JP2005528359A (ja) 2005-09-22
JP2005528359A5 true JP2005528359A5 (cg-RX-API-DMAC7.html) 2006-05-11

Family

ID=28454789

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003577780A Pending JP2005528359A (ja) 2002-03-20 2003-03-20 うつ病の治療のためのブプレノルフィンの投与方法

Country Status (12)

Country Link
US (1) US20030181475A1 (cg-RX-API-DMAC7.html)
EP (1) EP1485051B1 (cg-RX-API-DMAC7.html)
JP (1) JP2005528359A (cg-RX-API-DMAC7.html)
AT (1) ATE394097T1 (cg-RX-API-DMAC7.html)
AU (1) AU2003224742A1 (cg-RX-API-DMAC7.html)
CY (1) CY1108217T1 (cg-RX-API-DMAC7.html)
DE (1) DE60320770D1 (cg-RX-API-DMAC7.html)
DK (1) DK1485051T3 (cg-RX-API-DMAC7.html)
ES (1) ES2305457T3 (cg-RX-API-DMAC7.html)
PT (1) PT1485051E (cg-RX-API-DMAC7.html)
SI (1) SI1485051T1 (cg-RX-API-DMAC7.html)
WO (1) WO2003079945A1 (cg-RX-API-DMAC7.html)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5968547A (en) 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
EP1913938A1 (en) * 2002-12-13 2008-04-23 Euro-Celtique S.A. Transdermal buprenorphine dosage regimen for analgesia
US7270830B2 (en) * 2002-12-13 2007-09-18 Purdue Pharma L.P. Transdermal buprenorphine dosage regimen for analgesia
US8790689B2 (en) 2003-04-30 2014-07-29 Purdue Pharma L.P. Tamper resistant transdermal dosage form
BRPI0409945A (pt) 2003-04-30 2006-04-25 Purdue Pharma Lp forma de dosagem resistente à alteração
DE602004009449T2 (de) 2003-07-25 2008-07-24 Euro-Celtique S.A. Behandlung von entzug
DE10340428B4 (de) * 2003-09-02 2015-02-12 Acino Ag Opioides Analgetikum enthaltende transdermale Formulierung
FR2865650B1 (fr) * 2004-01-30 2008-06-13 Biocortech Utilisation du 14,15 dihydro 20,21-dinoreburnamenin14-ol pour traiter et/ou prevenir les depressions majeures et les desordres du cycle veille-sommeil
DE102004045599A1 (de) * 2004-09-17 2006-03-23 Grünenthal GmbH System zur sequentiellen, transdermalen Verabreichung von systemisch wirksamen Substanzen
DE102005007859A1 (de) * 2005-02-21 2006-08-24 Lts Lohmann Therapie-Systeme Ag Vefahren für eine medikamentöse Kombinations-Behandlung, sowie hierfür geeignete Arzneimittel-Kombinationen
DE102006011340A1 (de) * 2006-03-09 2007-09-20 Grünenthal GmbH Wirkstoffhaltige Pflaster mit verbesserter Handhabung
HUE043963T2 (hu) 2009-12-04 2019-09-30 Alkermes Pharma Ireland Ltd Morfinán származékok gyógyszer-túladagolás kezelésére
EP2608670B1 (en) 2010-08-23 2018-10-31 Alkermes Pharma Ireland Limited Methods for treating antipsychotic-induced weight gain
US10813925B2 (en) 2011-09-19 2020-10-27 Carmel—Haifa University Economic Corporation Ltd. Buprenorphine for the treatment of acute suicidality
US10195191B2 (en) 2011-12-15 2019-02-05 Alkermes Pharma Ireland Limited Opioid agonist antagonist combinations
US9211293B2 (en) 2011-12-15 2015-12-15 Alkermes Pharma Ireland Limited Opioid agonist antagonist combinations
SMT201800664T1 (it) * 2011-12-15 2019-01-11 Alkermes Pharma Ireland Ltd Samidorphan (alks 33) in combinazione con buprenorfina per il trattamento di disturbi depressivi
CA2858808C (en) * 2011-12-15 2017-04-18 Alkermes Pharma Ireland Limited Samidorphan (alks 33) in combination with opioid agonists
US9656961B2 (en) 2013-05-24 2017-05-23 Alkermes Pharma Ireland Limited Methods for treating depressive symptoms
ES2770978T3 (es) 2013-05-24 2020-07-06 Alkermes Pharma Ireland Ltd Análogos de morfanos y morfinanos y métodos de uso
CA2933733A1 (en) 2013-12-20 2015-06-25 Connie Sanchez Morillo Use of an opioid receptor antagonist with kappa-activity and vortioxetine for treatment of depressive disorder with melancholic features
WO2022101444A1 (en) 2020-11-12 2022-05-19 Alkermes Pharma Ireland Limited Immediate release multilayer tablet

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4806341A (en) * 1985-02-25 1989-02-21 Rutgers, The State University Of New Jersey Transdermal absorption dosage unit for narcotic analgesics and antagonists and process for administration
US5026556A (en) * 1988-11-10 1991-06-25 Norwich Eaton Pharmaceuticals, Inc. Compositions for the transdermal delivery of pharmaceutical actives
US4956171A (en) * 1989-07-21 1990-09-11 Paco Pharmaceutical Services, Inc. Transdermal drug delivery using a dual permeation enhancer and method of performing the same
US5240711A (en) * 1989-11-29 1993-08-31 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg Transdermal therapeutic system comprising as active component buprenorphine
AU637496B2 (en) * 1990-04-24 1993-05-27 Teijin Limited Plaster
US5069909A (en) * 1990-06-20 1991-12-03 Cygnus Therapeutic Systems Transdermal administration of buprenorphine
US5512593A (en) * 1993-03-02 1996-04-30 John S. Nagle Composition and method of treating depression using natoxone or naltrexone in combination with a serotonin reuptake inhibitor
US5613958A (en) * 1993-05-12 1997-03-25 Pp Holdings Inc. Transdermal delivery systems for the modulated administration of drugs
ATE218328T1 (de) * 1996-03-25 2002-06-15 Lohmann Therapie Syst Lts Transdermales therapeutisches system mit geringer applikationsdicke und hoher flexibilität sowie herstellungsverfahren
US6787149B1 (en) * 1996-12-12 2004-09-07 El Khoury And Stein Ltd. Topical application of opioid analgesic drugs such as morphine
US5968547A (en) * 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
US5900420A (en) * 1997-06-19 1999-05-04 Cole; William L. Method for treating chronic fatigue syndrome and fibromyalgia with buprenorphine
DE19738855C2 (de) * 1997-09-05 2001-01-04 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit haftklebender Reservoirschicht und unidirektional elastischer Rückschicht
DE19746191C2 (de) * 1997-10-18 2000-05-18 Lohmann Therapie Syst Lts Verfahren zur Anwendung eines Wirkstoff enthaltenden Pflasters zur Bekämpfung oder Linderung einer Sucht
EP1061924A1 (en) * 1998-03-09 2000-12-27 Trustees Of Tufts College Treatment of compulsive behaviours in man and animals
DE19840758A1 (de) * 1998-09-07 2000-03-09 Liedtke Pharmed Gmbh Systemische Therapie von Schmerz- und depressiver Befindlichkeit

Similar Documents

Publication Publication Date Title
CY1107262T1 (el) Θεραπεια της εξαρτησης στερησης
ATE311867T1 (de) Analgetische zusammensetzung enthaltend antiepileptische arzneistoffe und deren verwendungen
WO2001082914A3 (en) Topical anesthetic/opioid formulations and uses thereof
JP2009544619A5 (cg-RX-API-DMAC7.html)
UA88464C2 (ru) Способ дермального введения метадоновой композиции с обеспечением системного действия
DE60034667D1 (de) Pharmazeutische zusammensetzung aus komplexen kohlenhydraten deren anwendung
JP2004507496A5 (cg-RX-API-DMAC7.html)
JP2007500134A5 (cg-RX-API-DMAC7.html)
WO2004080413A3 (en) Uses and formulations for transdermal or transmucosal application of active agents
NZ592039A (en) Combination therapy for the treatment of ocular neovascular disorders
CY1108217T1 (el) Μεθοδος χορηγησης βουπρενορφινης για τη θεραπεια της καταθλιψης
HUP9801591A3 (en) Use of nitric oxide-releasing agents for producing pharmaceutical composition to treat impotency, and delivery device dosage of nitric oxide
WO2007012019A3 (en) Medicaments containing famotidine and ibuprofen and administration of same
JP2006513184A5 (cg-RX-API-DMAC7.html)
DK1572167T3 (da) Transdermal buprenophindoseringsbehandlingsplan for analgesi
AU5706301A (en) Topical formulations for the transdermal delivery of niacin and methods of treating hyperlipidemia
RU2002103808A (ru) Способ лечения болевого синдрома у онкологических больных
WO2003059284A3 (en) Composition and method for inhibiting hypersensitivity
BR0313305A (pt) Agente analgésico para indivìduos recém-nascidos ou fetais
DE60012575D1 (de) Nsaid enthaltendes wasserfreies gel zur topischen anwendung in der mundhöhle
RU2007106415A (ru) Способ лечения тяжелой формы вульгарных угрей
RU99107874A (ru) Способ лечения абстинентного синдрома у больных героиновой наркоманией
RU2003115786A (ru) Способ лечения пневмонии у новорожденных
Carlson Rituximab plus CHOP induction beneficial in aggressive NHL
RU99105224A (ru) Способ местного лечения свищевого дерматита